An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Senseonics Announces Equity Grants To Employees Under Inducement Plan
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Senseonics Holdings, Inc. (NYSE American: SENS) announced equity grants under its 2019 Inducement Plan to attract new employees. On January 4, 2022, three non-executive employees received options for 30,000 shares at an exercise price of $2.68 per share. The options vest over four years, contingent on employment status. Senseonics continues to pursue the development and availability of its Eversense Continuous Glucose Monitoring system globally, aiming to aid those living with diabetes.
Positive
Equity grants to new employees may enhance talent retention and recruitment.
Stock options priced at $2.68 provide an incentive linked to company growth.
Negative
None.
GERMANTOWN, Md.--(BUSINESS WIRE)--
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the “Plan”) in accordance with NYSE American Company Guide Section 711(a).
On January 4, 2022, Senseonics Compensation Committee granted 3 new non-executive employees non-qualified stock options to purchase an aggregate of 30,000 shares of the Company’s common stock as an inducement for such employees to join the Company. The options have an exercise price of $2.68 per share, which was the closing price of the Company’s common stock on the NYSE American on January 4, 2022. In each case, 25% of the shares underlying the options will vest on the first anniversary of the employee’s start date, with the remainder vesting in monthly installments over the subsequent three year period, in all cases contingent on such employee’s continued service with the Company at the applicable vesting date. Senseonics continues to work to bring its Eversense CGM System to more people with diabetes in the U.S. and other markets around the globe and drives to develop enhancements to the system.
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 90 days. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration twice per day, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see https://eversensediabetes.com/safety-info/.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics' CGM systems, Eversense® and Eversense® XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
Senseonics Investor Contact
Lynn Lewis or Philip Taylor Investor Relations
415-937-5406
investors@senseonics.com
Source: Senseonics Holdings, Inc.
FAQ
What equity grants did Senseonics announce on January 4, 2022?
Senseonics announced equity grants of stock options to three new employees, totaling 30,000 shares at an exercise price of $2.68 each.
What is the purpose of the equity grants from Senseonics?
The equity grants aim to induce new employees to join the company and enhance talent retention.
What is the Eversense CGM system?
Eversense is a Continuous Glucose Monitoring system designed for individuals aged 18 and older, providing glucose level measurements for up to 90 days.
